Search Results for keywords:"National Cancer Institute"

The National Cancer Institute has announced a change to an upcoming meeting of the Special Emphasis Panel, originally scheduled for March 3, 2025. The new date for the meeting is March 4, 2025, and it will still take place from 11 a.m. to 4 p.m. The meeting is set to be held virtually, but it remains closed to the public. These details were published in the Federal Register as an amendment to a previous notice.

The National Cancer Institute has announced several closed meetings in accordance with the Federal Advisory Committee Act. These meetings will not be open to the public to protect sensitive information like trade secrets and personal details of individuals involved in grant applications and contract proposals. Notable meetings include sessions to evaluate contract proposals and grant applications relating to cancer research, occurring throughout March 2021. For more information, individuals can contact the Scientific Review Officers listed in the notice.

The National Cancer Institute announced a series of meetings that will be closed to the public according to the Federal Advisory Committee Act. These meetings, scheduled for April 10-11, 2025, will focus on reviewing grant applications and are closed to prevent the disclosure of confidential information. The review sessions will take place virtually and will evaluate proposals, including potentially sensitive commercial or personal details. Interested parties may contact Jeffrey E. DeClue for further information.

The National Cancer Institute, part of the National Institutes of Health, is considering giving Iovance Biotherapeutics, Inc. an exclusive patent license. This license would allow Iovance to develop and sell specific cancer treatment products using a patented method involving engineered cells that could improve anti-tumor action. Interested parties have until March 12, 2021, to submit comments or objections. This license could cover worldwide rights and mainly focuses on treating several types of cancers, excluding certain specific methods.

The National Cancer Institute announced a series of closed meetings to review and evaluate grant applications and contract proposals. These meetings will occur virtually from February 24 to March 11, 2025, and involve discussions about potential confidential information. The confidentiality is due to concerns about disclosing trade secrets, commercial property, and personal information related to individuals connected with the proposals. Details for each meeting, including dates, times, and contact information, have been provided for transparency and record-keeping purposes.

The National Cancer Institute announced a virtual meeting of the National Cancer Advisory Board, which will be partially open to the public. The meeting is scheduled for February 11, 2021. During the open session, board members will discuss various reports and agenda items, while the closed session will focus on evaluating grant applications. Interested individuals are encouraged to contact the executive secretary for comments or accommodations and can find additional details and the agenda on the Institute's website.

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS), is planning to grant an exclusive license to StraightLine Bio, Inc. for certain anti-cancer inventions. These inventions involve patents related to T cell receptors targeting a cancer antigen called KK-LC-1, which is found in certain epithelial cancers. The proposed license would allow StraightLine Bio to develop and commercialize therapies using this technology worldwide, but with some specific exclusions. The public has a chance to comment or object to this plan until December 26, 2024.

The National Cancer Institute announced several upcoming closed meetings to review grant applications and contract proposals. These meetings will not be open to the public to protect confidential information and personal privacy. Each meeting is led by a Scientific Review Officer, and the topics include reviews for SBIR contracts, clinical and translational research, and various other cancer research initiatives. The meetings will take place via telephone conference calls from late February through early April 2021.

The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Kyverna Therapeutics for technology involving chimeric antigen receptors (CARs) that target the CD19 protein. This technology is aimed at creating a treatment for autoimmune diseases using a patient’s own altered T lymphocytes. The license could cover worldwide territories and would allow Kyverna to develop, produce, and market this therapy. Public comments or objections about the patent license need to be submitted by March 5, 2021.

The National Cancer Institute has announced a closed meeting to take place on May 9, 2025. This meeting, part of the Federal Advisory Committee Act, will review and evaluate contract proposals and will be held virtually. Confidentiality will be maintained to protect sensitive trade secrets and personal privacy. The session will run from 9:00 a.m. to 6:00 p.m., and any inquiries can be directed to Shamala K. Srinivas, Ph.D.